Skip to main content
. 2018 Mar 28;77(8):1107–1117. doi: 10.1136/annrheumdis-2018-213131

Table 1.

Recommendations for diagnosis and screening in juvenile idiopathic arthritis (JIA)-related uveitis

Recommendation L S Agreement (%) References
1. All patients in whom a diagnosis of JIA is being considered should be screened for uveitis according to a contemporary and audited protocol. Formal screening protocol should be administered in all centres, where patients with JIA are seen. 2A B 100 13–32
2. Frequency of ophthalmological follow-up visits must be based on disease severity and needs to be decided in conjunction with an expert ophthalmologist. 4 D 100 13–27 33–66
3. Patients with JIA stopping any systemic immunosuppressant are at risk of developing new onset uveitis or recurrence of uveitis after a prolonged remission. After stopping systemic immunosuppression, it is recommended that all patients with JIA are screened by an ophthalmologist at least every three months for at least 1 year. 2B B 100 67–70

Agreement indicates the % of experts that agreed on the recommendation during the final voting round of the consensus meeting.

1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, cohort studies; 2B, case–control studies; 3, non-comparative descriptive studies; 4, expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated from level 3 or 4 expert opinion. L, level of evidence; S, strength of evidence.